Med Sci Monit (2020) 26:e920989
Yes, all credible peptide therapies for weight loss and blood sugar control require a prescription from a licensed healthcare professional
Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study
Schedule a complimentary consultation, either virtually or in person, with one of our dedicated providers
First approved dual GIP and GLP-1 receptor co-agonist one molecule activating both incretin receptors simultaneously
Daniel Drucker's 2018 synthesis of GLP-1 pharmacology in Cell Metabolism lays out the four core actions that make the hormone useful: it stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to enhance satiety (Drucker, 2018)